The health and economic effects of HPV DNA screening in the Netherlands

International Journal of Cancer

Volumn 127, Issue 9, 2010, Pages 2147-2158

  Berkhof, Johannes ^a   Coupé, Veerle M ^a   Bogaards, Johannes A ^a   Van Kemenade, Folkert J ^a   Helmerhorst, Theo J ^b   Snijders, Peter J ^a   Meijer, Chris J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

cervical cancer; cost effectiveness; human papillomavirus; mathematical model; screening

Indexed keywords

VIRUS DNA;

ARTICLE; CALIBRATION; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA SCREENING; ECONOMIC ASPECT; FEMALE; GYNECOLOGICAL EXAMINATION; HUMAN; NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VERRUCA VULGARIS; WART VIRUS; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; MASS SCREENING; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PROBABILITY; QUALITY OF LIFE; TIME; UTERINE CERVIX TUMOR; VAGINA SMEAR;

COST-BENEFIT ANALYSIS; DNA, VIRAL; FEMALE; HUMANS; MARKOV CHAINS; MASS SCREENING; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; QUALITY OF LIFE; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77956638411     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25211     Document Type: Article

References (68)

1. Ault KA,. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861 -8.
2. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928 -43.
3. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G,. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247 -55.
4. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T,. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095 -101.
5. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J,. Chapter 9: clinical applications of HPV testing: A summary of meta-analyses. Vaccine 2006; 24 (Suppl 3): S78 -S89.
6. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, van Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94 -101.
7. Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, Franco EL,. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006; 119: 615 -23.
8. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589 -97.
9. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla PP, Del MA, De ML, De LM, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547 -55.
10. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla PP, Del MA, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765 -74.
11. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, Sargent A, Peto J,. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006; 95: 56 -61.
12. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764 -72.
13. Berkhof J, de Bruijne MC, Zielinski GD, Meijer CJ,. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in The Netherlands. Int J Cancer 2005; 115: 268 -75.
14. Berkhof J, de Bruijne MC, Zielinski GD, Bulkmans NW, Rozendaal L, Snijders PJ, Verheijen RH, Meijer CJ,. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006; 118: 1759 -68.
15. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N,. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12 -9.
16. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ,. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518 -27.
17. Nobbenhuis MA, Helmerhorst TJ, van Den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ,. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001; 358: 1782 -3.
18. Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, Snijders PJ, Meijer CJ,. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007; 96: 1419 -24.
19. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M,. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 46 -52.
20. Gustafsson L, Adami HO,. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer 1989; 60: 132 -41.
21. van Oortmarssen GJ, Habbema JD,. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991; 64: 559 -65.
22. Bos AB, van Ballegooijen M, van Oortmarssen GJ, van Marle ME, Habbema JD, Lynge E,. Non-progression of cervical intraepithelial neoplasia estimated from population-screening data. Br J Cancer 1997; 75: 124 -30.
23. Schiffman M, Rodriguez AC,. Heterogeneity in CIN3 diagnosis. Lancet Oncol 2008; 9: 404 -406.
24. Bulk S, Bulkmans NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RH, Snijders PJ, Meijer CJ,. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 2007; 121: 361 -7.
25. Berkhof J, Bulkmans NW, Bleeker MC, Bulk S, Snijders PJ, Voorhorst FJ, Meijer CJ,. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 2006; 15: 1268 -73.
26. Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ,. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008; 98: 646 -51.
27. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ,. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 20 -5.
28. Nobbenhuis MA, Meijer CJ, van Den Brule AJ, Rozendaal L, Voorhorst FJ, Risse EK, Verheijen RH, Helmerhorst TJ,. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001; 84: 796 -801.
29. Rozendaal L, Westerga J, van der Linden JC, Walboomers JM, Voorhorst FJ, Risse EK, Boon ME, Meijer CJ,. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 2000; 53: 606 -11.
30. Ostor AG,. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186 -92.
31. Ketting BW,. Surgical treatment of invasive carcinoma of the uterine cervix. Amsterdam: University of Amsterdam, 1981. 154 p.
32. Herbert A, Singh N, Smith JA,. Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire. Cytopathology 2001; 12: 26 -36.
33. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB,. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327: 1272 -8.
34. van Ballegooijen M, Boer R, van Oortmarssen GJ, Koopmanschap MA, Lubbe JThN, Habbema JDF,. Bevolkingsonderzoek op baarmoederhalskanker: leeftijdsgrenzen en intervallen. Een geactualiseerde kosten-effectiviteits analyse. Rotterdam: Instituut Maatschappelijke Gezondheidszorg, Erasmus Universiteit Rotterdam, 1993. 96 p.
35. Visser O, Siesling S, van Dijck JA, eds. Incidence of cancer in The Netherlands 1999/2000. Utrecht: Vereniging van Integrale Kankercentra (), 2003. 65 p.
36. van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema D,. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering. Rotterdam: Instituut Maatschappelijke Gezondheidszorg, Erasmus Universiteit Rotterdam, 2006. 72 p.
37. Rebolj M, van Ballegooijen M, Berkers LM, Habbema D,. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in The Netherlands. Int J Cancer 2007; 120: 806 -12.
38. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K,. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 2372 -81.
39. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E,. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604 -15.
40. Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A,. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Cancer 2005; 92: 990 -4.
41. Jacobs MV, Snijders PJ, van Den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM,. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35: 791 -5.
42. van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD,. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002; 94: 193 -204.
43. Hopman EH, Kenemans P, Helmerhorst TJ,. Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Obstet Gynecol Surv 1998; 53: 97 -106.
44. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJLM,. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardization since 1996. J Clin Pathol 2004; 57: 388 -93.
45. Rodenburg-van Dieten HE,. Richtlijnen voor farmaco-economisch onderzoek; evaluatie en actualisatie. Diemen: College voor zorgverzekeringen (), 2005. 29 p.
46. Drummond MF, O'Brien B, Stoddart GL, Torrance GW,. Methods for the economic evaluation of health care programmes, second edition ed. Oxford: Oxford University Press, 1997. 305 p.
47. Kim JJ, Ortendahl J, Goldie SJ,. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009; 151: 538 -45.
48. Goldie SJ, Kim JJ, Wright TC,. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004; 103: 619 -31.
49. Kim JJ, Wright TC, Goldie SJ,. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005; 97: 888 -95.
50. Sherlaw-Johnson C, Philips Z,. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer 2004; 91: 84 -91.
51. Muhlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U,. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. Int J Technol Assess Health Care 2008; 24: 184 -92.
52. Bistoletti P, Sennfalt K, Dillner J,. Cost-effectiveness of primary cytology and HPV DNA cervical screening. Int J Cancer 2008; 122: 372 -6.
53. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ,. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008; 100: 308 -20.
54. Bidus MA, Maxwell GL, Kulasingam S, Rose GS, Elkas JC, Chernofsky M, Myers ER,. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol 2006; 107: 997 -1005.
55. Kulasingam S, Rajan R, St. Pierre Y, Atwood CV, Myers E, Franco E,. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med 2009; 7: 69.
56. Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C,. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol 2009; 112: 377 -83.
57. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ,. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166: 137 -50.
58. Bogaards JA, Xiridou M, Coupe VM, Meijer CJ, Wallinga J, Berkhof J,. Model-based estimation of viral transmissibility and infection-induced resistance from the cross-sectional age-dependent prevalence of infection for 14 high-risk human papillomavirus types. Am J Epidemiol, in press.
59. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ,. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med 2008; 168: 1881 -9.
60. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101: 88 -99.
61. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL,. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579 -88.
62. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ,. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516 -20.
63. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10: 672 -82.
64. Sasieni P, Castle PE, Cuzick J,. Further analysis of the ARTISTIC trial. Lancet Oncol 2009; 10: 841 -2.
65. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ,. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26 (Suppl 10): K29 -K41.
66. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M,. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072 -9.
67. Carozzi F, Confortini M, Palma PD, Del MA, Gillio-Tos A, De ML, Giorgi-Rossi P, Pontenani G, Rosso S, Sani C, Sintoni C, Segnan N, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008; 9: 937 -45.
68. Overmeer RM, Henken FE, Snijders PJ, Claassen-Kramer D, Berkhof J, Helmerhorst TJ, Heideman DA, Wilting SM, Murakami Y, Ito A, Meijer CJ, Steenbergen RD,. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol 2008; 215: 388 -97.